SCHEMBL29235196

SCHEMBL29235196

CC(C)(C)OC(=O)c1ccc(Br)cc1C1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR Q13258 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.47
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
GABRA1 P14867 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
GABRA2 P47869 2/20 0.39
GABRA6 Q16445 2/20 0.39
GABRA4 P48169 1/20 0.39
USP30 Q70CQ3 2/20 0.38
AAK1 Q2M2I8 3/20 0.37
KRAS P01116 1/20 0.36
GABRB2 P47870 1/20 0.35
CACNA1B Q00975 1/20 0.34
CAMKK2 Q96RR4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19900027 0.94 PTGDR (0.40) PTGDRPTGDR2KDM4EMEN1MAPT
SCHEMBL27172075 0.84 PTGDR (0.50) PTGDRPTGDR2KDM4EMEN1MAPT
SCHEMBL20412793 0.80 TP53 (0.45) MEN1MAPTKMT2AUSP30KRAS
SCHEMBL15567556 0.78 NR4A2 (0.47) PTGDRPTGDR2KDM4EMAPTALDH1A1
SCHEMBL27172001 0.78 FPR2 (0.48) USP30
SCHEMBL27171876 0.78 FPR2 (0.48) USP30
SCHEMBL30074465 0.78 FPR2 (0.48) USP30
SCHEMBL1620627 0.77 PTGDR (0.55) PTGDRPTGDR2KDM4EMEN1MAPT
SCHEMBL16423371 0.77 GAA (0.40) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL4628583 0.77 CES2 (0.41) PTGDR2KDM4EGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145607-A1 Modulators of CAMKK2 as Ligand Directed Degraders CELGENE CORPORATION (US) 2025-05-08 US disclosed
EP-4412999-A1 MODULATORS OF CAMKK2 AS LIGAND DIRECTED DEGRADERS Celgene Corporation (US) 2024-08-14 EP disclosed
CN-118076603-A CAMKK2 modulators as ligand-directed degradants 细胞基因公司 2024-05-24 CN disclosed
WO-2023059873-A1 MODULATORS OF CAMKK2 AS LIGAND DIRECTED DEGRADERS CELGENE CORPORATION (US) 2023-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145607-A1 Modulators of CAMKK2 as Ligand Directed Degraders CAMKK2, CAMKK1, CAMK1D PTGDR 1013/4885PTGDR2 719/4885KDM4E 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.